<DOC>
	<DOC>NCT01143753</DOC>
	<brief_summary>This open-label, multi-center study will evaluate the safety, tolerability, and pharmacokinetics of RO5212054 [PLX3603] in participants with BRAF V600-mutated advanced solid tumors. Cohorts of participants will receive escalating oral doses of RO5212054. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor Doseescalation phase: Histologically confirmed, newly diagnosed or relapsed/ refractory unresectable American Joint Committee on Cancer (AJCC) Stage IIIC or IV disease Eastern Cooperative Oncology Group (ECOG) performance status 01 Adequate liver, renal and bone marrow function Participants for whom standard therapy exists and is considered appropriate by the investigator Prior treatment with an inhibitor of BRAF (sorafenib allowed) Active Central nervous system (CNS) lesions, or history of or known carcinomatous meningitis Treatment with any chemotherapy, radiotherapy, immunotherapy or investigational agent within 28 days prior to first dose of study drug Anticipated or ongoing anticancer therapies other than those administered in this study Serious cardiovascular illness within the 6 months prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>